TY - JOUR
T1 - Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts
AU - Berg Luecke, Linda
AU - Waas, Matthew
AU - Littrell, Jack
AU - Wojtkiewicz, Melinda
AU - Castro, Chase
AU - Burkovetskaya, Maria
AU - Schuette, Erin N.
AU - Buchberger, Amanda Rae
AU - Churko, Jared M.
AU - Chalise, Upendra
AU - Waknitz, Michelle
AU - Konfrst, Shelby
AU - Teuben, Roald
AU - Morrissette-McAlmon, Justin
AU - Mahr, Claudius
AU - Anderson, Daniel R
AU - Boheler, Kenneth R.
AU - Gundry, Rebekah L.
N1 - Funding Information:
This work was supported by the National Institutes of Health (R01-HL134010, R01-HL126785 and R35-HL155460 to R.L.G.; R01-HL152249 to K.R.B.; F31-HL140914 to M.W.; and TL1TR001437 to L.B.L); the American Heart Association (20PRE35200049 to L.B.L); and the Maryland Stem Cell Research Fund (2020-MSCRFD-5430 to K.R.B.). L.B.L. is a member of the Medical College of Wisconsin Medical Scientist Training Program, which is partially supported by a T32 grant from the National Institute of General Medical Sciences (GM080202). Funding sources were not involved in study design, data collection, interpretation, analysis or publication. We are thankful to B. Wollscheid for fruitful discussions and assistance with catalyst selection and W. Zhou for assistance with cell culture. We are thankful to W. Bussey, J. Miller, R. Ruskamp, K. Campbell, C. Hancock-Friesen and J. Um for assistance with specimen collections. Some specimens and data used in this study were provided by the Nebraska Cardiovascular Biobank and Registry, which is supported by the Center for Heart and Vascular Research. Flow cytometry was performed using instrumentation in the University of Nebraska Medical Center Flow Cytometry Research Facility, administrated through the Office of the Vice Chancellor for Research and supported by state funds from the Nebraska Research Initiative and the Fred and Pamela Buffett Cancer Center’s National Cancer Institute Cancer Support Grant. Major instrumentation has been provided by the Office of the Vice Chancellor for Research, the University of Nebraska Foundation, the Nebraska Banker’s Fund and the NIH-NCRR Shared Instrument Program.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Cardiac cell surface proteins are drug targets and useful biomarkers for discriminating among cellular phenotypes and disease states. Here we developed an analytical platform, CellSurfer, that enables quantitative cell surface proteome (surfaceome) profiling of cells present in limited quantities, and we apply it to isolated primary human heart cells. We report experimental evidence of surface localization and extracellular domains for 1,144 N-glycoproteins, including cell-type-restricted and region-restricted glycoproteins. We identified a surface protein specific for healthy cardiomyocytes, LSMEM2, and validated an anti-LSMEM2 monoclonal antibody for flow cytometry and imaging. Surfaceome comparisons among pluripotent stem cell derivatives and their primary counterparts highlighted important differences with direct implications for drug screening and disease modeling. Finally, 20% of cell surface proteins, including LSMEM2, were differentially abundant between failing and non-failing cardiomyocytes. These results represent a rich resource to advance development of cell type and organ-specific targets for drug delivery, disease modeling, immunophenotyping and in vivo imaging.
AB - Cardiac cell surface proteins are drug targets and useful biomarkers for discriminating among cellular phenotypes and disease states. Here we developed an analytical platform, CellSurfer, that enables quantitative cell surface proteome (surfaceome) profiling of cells present in limited quantities, and we apply it to isolated primary human heart cells. We report experimental evidence of surface localization and extracellular domains for 1,144 N-glycoproteins, including cell-type-restricted and region-restricted glycoproteins. We identified a surface protein specific for healthy cardiomyocytes, LSMEM2, and validated an anti-LSMEM2 monoclonal antibody for flow cytometry and imaging. Surfaceome comparisons among pluripotent stem cell derivatives and their primary counterparts highlighted important differences with direct implications for drug screening and disease modeling. Finally, 20% of cell surface proteins, including LSMEM2, were differentially abundant between failing and non-failing cardiomyocytes. These results represent a rich resource to advance development of cell type and organ-specific targets for drug delivery, disease modeling, immunophenotyping and in vivo imaging.
UR - http://www.scopus.com/inward/record.url?scp=85162110173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162110173&partnerID=8YFLogxK
U2 - 10.1038/s44161-022-00200-y
DO - 10.1038/s44161-022-00200-y
M3 - Article
C2 - 36950336
AN - SCOPUS:85162110173
SN - 2731-0590
VL - 2
SP - 76
EP - 95
JO - Nature Cardiovascular Research
JF - Nature Cardiovascular Research
IS - 1
ER -